MAKE DUPIXENT YOUR CHOICE IN PN FOR ADULTS

In prurigo nodularis,

DUPIXENT demonstrated significant improvement in itch and nodule clearance1,2

≈3x

as many patients had significantly reduced itch in PRIME at Week 24 (60% vs 18%) with DUPIXENT vs placebo;
P<0.0001 [primary endpoint]

PRIME2

  • 37% of DUPIXENT patients achieved clinically meaningful itch response vs 22% with placebo at Week 12; P=0.0216 [primary endpoint]. At Week 24, 58% of DUPIXENT patients achieved significant itch relief vs 20% with placebo;
    P<0.0001 [secondary endpoint]

≈2.5x

as many patients achieved significant nodule clearance in PRIME at Week 24 (48% vs 18%) with DUPIXENT vs placebo; P=0.0004 [secondary endpoint]

PRIME2

  • 45% of DUPIXENT patients
    similarly achieved significant
    nodule clearance (IGA PN-S 0 or 1)
    vs 16% with placebo at Week 24;
    P<0.0001 [secondary endpoint]

Demonstrated
safety profile

across 2 PN trials

Most common adverse reactions in adult patients with PN (incidence ≥2%) were nasopharyngitis, conjunctivitis, herpes infection, dizziness, myalgia, and diarrhea

View Efficacy and
safety overview See clinical study designs

IGA PN-S, Investigator’s Global Assessment PN-Stage.

One dose every 2 weeks (after an initial loading dose of two subcutaneous injections)2

DUPIXENT does not require initial lab testing or ongoing lab monitoring according to the Prescribing Information.2

DUPIXENT is available in a 300 mg pre-filled pen or pre-filled syringe.

See DosAGE and Administration

Samples may be available—speak with your DUPIXENT representative for more information, or click here to contact a representative.

Enroll your patients in

DUPIXENT MyWay is a patient support program that can help enable access to DUPIXENT and offers financial assistance for eligible patients, one-on-one nursing support, and more.

LEARN HOW WE CAN HELP

DUPIXENT MyWay
ENROLLMENT FORMS
FOR DERMATOLOGISTS
English Enrollment Form
Spanish Enrollment Form